BioNTech News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

16.09.24	144: Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing (RSS)
13.09.24	144: Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing (RSS)
05.09.24	6-K: Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act (RSS)
22.08.24	6-K: Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act (RSS)
19.08.24	6-K: Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act (RSS)
16.08.24	6-K: Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act (RSS)
07.08.24	6-K: Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act (RSS)
06.08.24	6-K: Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act (RSS)
05.08.24	6-K: Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act (RSS)
30.07.24	6-K: Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act (RSS)
29.01.24	EQS-News: ROSEN, LEADING TRIAL ATTORNEYS, Encourages BioNTech SE Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - BNTX (EQS Group)
26.01.24	EQS-News: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX (EQS Group)
24.01.24	EQS-News: ROSEN, A RANKED AND LEADING FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX (EQS Group)
22.01.24	EQS-News: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX (EQS Group)
21.01.24	EQS-News: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages BioNTech SE Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - BNTX (EQS Group)
19.01.24	EQS-News: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages BioNTech SE Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - BNTX (EQS Group)
09.01.24	6-K: Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act (RSS)
04.01.24	144: Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing (RSS)
23.10.23	6-K: Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act (RSS)
16.10.23	6-K: Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act (RSS)
10.10.23	144/A: Amendment to a previously filed 144 (RSS)
29.09.23	144: Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing (RSS)
11.09.23	6-K: Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act (RSS)
14.08.23	144/A: Amendment to a previously filed 144 (RSS)
14.08.23	6-K: Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act (RSS)
07.08.23	6-K: Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act (RSS)
29.06.23	6-K: Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act (RSS)
28.06.23	144: Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing (RSS)
08.05.23	6-K: Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act (RSS)
13.04.23	6-K: Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act (RSS)
03.04.23	6-K: Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act (RSS)
27.03.23	20-F: Registration of securities of foreign private issuers pursuant to section 12(b) or (g) (RSS)
27.03.23	6-K: Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act (RSS)
15.03.23	6-K: Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act (RSS)
22.02.23	Redhook Brewing Launches Redhook 81, Celebrating Pacific Northwest Roots and the Spirit of Hard Work (RSS)
14.02.23	SC 13G/A: An amendment to the SC 13G filing (RSS)
13.02.23	S-3ASR: S-3ASR (RSS)
13.02.23	10-Q: Quarterly report which provides a continuing view of a company's financial position (RSS)
10.01.23	6-K: Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act (RSS)
08.12.22	Attention Craft Beer Fans! Tilray Beverages Highlights Boldest Brews For Summer (RSS)
30.11.22	6-K: Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act (RSS)
18.11.22	4: Statement of changes in beneficial ownership of securities (RSS)
16.03.20	BioNTech berichtet über rapide Fortschritte bei COVID-19-Impfstoff-Programm zur Bekämpfung der globalen Gesundheitsbedrohung (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

08.11.25		Oktober 2025: So schätzen Experten die Novartis-Aktie ein
08.11.25		Roche-Aktie: Einschätzungen und Kursziele der Analysten im Oktober
07.11.25		Goldman Sachs Group Inc. bescheinigt Buy für Fresenius Medical Care (FMC) St-Aktie
07.11.25		Bayer-Aktie unter Druck: Neue Studie bestätigt Potenzial von Finerenon - neue Finanzspitze gefunden
07.11.25		DAX 40-Titel Bayer-Aktie: So viel hätten Anleger an einem Bayer-Investment von vor 5 Jahren verloren
07.11.25		SMI-Papier Roche-Aktie: So viel Verlust hätte ein Roche-Investment von vor 3 Jahren eingefahren
06.11.25		J&J-Aktie grün: Johnson & Johnson Innovative Medicine ab Januar mit neuem Schweiz-Chef
06.11.25		Moderna-Aktie zieht kräftig an: Bessere Umsatz- und Ergebniszahlen als erwartet

08.11.25

Oktober 2025: So schätzen Experten die Novartis-Aktie ein

08.11.25

Roche-Aktie: Einschätzungen und Kursziele der Analysten im Oktober

07.11.25

Goldman Sachs Group Inc. bescheinigt Buy für Fresenius Medical Care (FMC) St-Aktie

07.11.25

Bayer-Aktie unter Druck: Neue Studie bestätigt Potenzial von Finerenon - neue Finanzspitze gefunden

07.11.25

DAX 40-Titel Bayer-Aktie: So viel hätten Anleger an einem Bayer-Investment von vor 5 Jahren verloren

07.11.25

SMI-Papier Roche-Aktie: So viel Verlust hätte ein Roche-Investment von vor 3 Jahren eingefahren

06.11.25

J&J-Aktie grün: Johnson & Johnson Innovative Medicine ab Januar mit neuem Schweiz-Chef

06.11.25

Moderna-Aktie zieht kräftig an: Bessere Umsatz- und Ergebniszahlen als erwartet

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Swisscom	603.00	1.94 %	K V
Roche Hldg G	268.40	1.21 %	K V
Givaudan	3’354.00	1.18 %	K V
Nestle	79.12	0.29 %	K V
Zurich Insur Gr	566.60	0.25 %	K V
ABB	56.12	-0.81 %	K V
CieFinRichemont	154.95	-0.96 %	K V
UBS Group	30.35	-1.40 %	K V
Logitech Intl	94.94	-1.47 %	K V

BioNTech Aktie VALOR 50030055 / ISIN US09075V1026

Nachrichten zu BioNTech (ADRs)

Aktien Top/Flop

BioNTech Peer Group Nachrichten

Meistgelesene Nachrichten